APA (7th ed.) Citation

AG, D., E, V., N, G., P, D. P., A, A., A, O., . . . JJ, P. R. (2022). Exposure-response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma. Cancer chemotherapy and pharmacology, 89(2), 151. https://doi.org/10.1007/s00280-021-04381-4

Chicago Style (17th ed.) Citation

AG, Dosne, Valade E, Goeyvaerts N, De Porre P, Avadhani A, O'Hagan A, Li LY, Ouellet D, and Perez Ruixo JJ. "Exposure-response Analyses of Erdafitinib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma." Cancer Chemotherapy and Pharmacology 89, no. 2 (2022): 151. https://doi.org/10.1007/s00280-021-04381-4.

MLA (9th ed.) Citation

AG, Dosne, et al. "Exposure-response Analyses of Erdafitinib in Patients with Locally Advanced or Metastatic Urothelial Carcinoma." Cancer Chemotherapy and Pharmacology, vol. 89, no. 2, 2022, p. 151, https://doi.org/10.1007/s00280-021-04381-4.